Shopping Cart (0)
My Account

Your Shopping Cart
ISEV2014 Educational EventBiofluid Biopsies and Companion Diagnostics 2014Clinical Applications of Mass SpectrometryFood Analysis CongressAdvances in Stem Cell Research 2014 - Online Event20% Discount OfferePoster Award PrizeBlogs

Companion Diagnostics and Personalized Medicine Market Report 2012

Publisher: Select Biosciences
Published: August 2012
Pages: 130

Price:



Up-to-Date Market Analyses of the CDx Field

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace.  Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient population—the field of stratified medicine.

Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report we describe the current state of the marketplace from the following perspectives:

  • All the Prognostic and Predictive Biomarkers with Potential Clinical Utility are described—a few have already been developed into CDx and we expect growth in this space
  • Targeted Therapeutics, Associated Biomarkers, Therapeutic Indications, and Testing Mandates are Described
  • Companion Diagnostics Partnerships and Collaborations from 2009 to 2012 are Presented—Provides an Up-to-Date State of the Industry Describing the Disease Areas being Addressed and Types of Biomarkers Being Deployed
  • Quantitative Market Metrics
    • Quantitative Market Forecast: Market Sizing and Growth Rate
    • Revenue Breakout: Rx versus Dx
    • Targeted Rx and CDx Pricing
  • Publication Hotspot Analyses of the Various Cancer Biomarker Classes for Identifying Niches of Market Opportunity in Various Disease Classes

This data-driven characterization of the Companion Diagnostics and Personalized Medicine field is a hands-on document that can be used for competitive benchmarking, business planning, and strategy development—all the data that have been collected in this industry analysis are presented and they form the basis for the conclusions drawn throughout the market report presented in a format enabling “drag-and-drop” into business presentations/business plans—this Market Report is written and delivered to customers in PowerPoint format.

Extensive Market Analyses Presented in this Report

Personalized Medicine and Companion Diagnostics: Market Segmentation and Quantitative Analysis

  • Prognostic Biomarkers in Cancer Listing, Description, and Clinical Significance
  • Predictive Biomarkers in Cancer Listing, Description, and Clinical Significance
  • Summary of Pathways to Regulatory Approval of Companion Diagnostics
  • LDTs under CLIA Certification
  • Outcomes with Drugs in Various Disease Classes
  • Percent of Tumor Classes where Tumors are Associated with Characterized Somatic Mutations
  • Companion Diagnostics and Personalized Medicine: Quantitative Market Metrics
    • How Much Does it Cost to Develop a Companion Diagnostic?
    • Precedent for Premium Pricing in Cancer Targeted Therapeutics
    • Pricing of Selected Personalized Medicine Tests
    • Growth of the Personalized Medicine Marketplace: Market Size/Forecast and Growth Rate

Personalized Medicine Industry Landscape: Selected Indications, Biomarkers and Therapeutics

Market Trends and Evolution of the CDx Marketplace

  • Disparities between Rx and CDx Companies
  • Varying Economic Incentives between Rx and Dx Development
  • Increasing Targeted Rx in the Oncology Space and Effect on CDx Development
  • Current Rx/CDx Co-development Programs in Phase III Trials with Listing of Associated Biomarkers
  • Cancer Classes Addressable by CDx
  • Characterization of Molecular Biomarker Classes: Hotspot Analysis of Publications
    • Cancer Biomarkers
    • Oncogenes
    • Tumor Suppressor Genes
    • Non-coding RNAs
  • Collaborations and Partnering in the CDx Space
    • 2012
    • 2011
    • 2010
    • 2009

Report Table of Contents (TOC) [Click Here to Download PDF File]


For enquiries about this market report, please contact Kathy Gray at Kathy.Gray@Selectbiosciences.com

Conference News
Papers Presented in the Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference can be Published in CSBJ
Papers Presented in the Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference can be Published in CSBJ
Computational and Structural Biotechnology Journal [CSBJ (ISSN 2001-0370)] will devote a conference special issue comprising of selected articles from the speakers/oral and poster presenters of Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference. Selected authors will receive an invitation to submit full length manuscripts to CSBJ. The full length manuscripts will undergo the peer-review process as per CSBJ policies. From July-2014, CSBJ will be part of ELSEVIER Open-access


Keynote Speakers Confirmed, Carlos Caldas and Mark Caulfield
We are thrilled to announce that Professor Carlos Caldas, Group Leader at the Cancer Research UK Cambridge Institute and Professor Mark Caufield, Chief Scientist of the Genomics England 100,000 project, have both confirmed their keynote presentations at Personalized Medicine in May 2015, Cambridge.


Call for papers - Advances in qPCR and dPCR 2015, Singapore
Call for papers - Advances in qPCR and dPCR 2015, Singapore
We are now accepting papers for the Advances in qPCR and dPCR meeting which will take place on the 21-22 May 2015 in Singapore.


Challenges and Advances in Targeted and Non-Targeted Analysis of Chemical Contaminants and Adulterants
This workshop will discuss various challenges in the analysis of chemical contaminants and adulterants in food and food supplements and demonstrate on real-life examples how advanced analytical methods can address them.


Keynote Speaker Confirmed, Marcie Glicksman
We are thrilled to announce that Marcie Glicksman, Co-Director of the Lab for Drug Discovery, at the Harvard NeuroDiscovery Center, has confirmed she will be giving a keynote presentation at Academic Drug Discovery 2015.


LAB-ON-A-CHIP ASIA - EARLY BIRD
LAB-ON-A-CHIP ASIA - EARLY BIRD
SAVE UP TO S$150 - EARLY BIRD DEADLINE 10 OCTOBER 2014. Don't miss out - register today!

Scroll Up
Scroll Down
Keep me updated Select Bio Blog LinkedIn Twitter LabTube.tv SBOnDemand.com MarketReports.com Research-Store.com